We invite you to listen to an in-depth discussion of CIBRN Question #5 & Question #6, as presented by Dr. Gordon Searles, Dr. Ronald Vender and Dr. Mark Kirchhof, recorded at the CIBRN Dermatology Webinar, December 8, 2016. Link to recorded webinar.
CIBRN Question #5: Given that biosimilar trials are to be compared against the originator using a “most sensitive” indication or condition, how will the trial indication be selected for study? Link to discussion on Sosido.
CIBRN Question #6: Can the concept of extrapolation be used for biosimilars in patients with hidradenitis suppurativa given their major treatment differences? Link to discussion on Sosido.
Please join Dr. Gordon Searles, Dr. Ronald Vender and Dr. Mark Kirchhof for an in-depth discussion of CIBRN Question #5 and Question #6 surrounding the implications of the evolving Biosimilar landscape on clinical practice and patient health in Canada.
This webinar is intended for the CIBRN Dermatology subgroup and is scheduled for Thursday, December 8th, 7:00-8:00pm EST. See instructions below:
Step 1: To join the audio portion:
Dial toll-free: 1-866-830-9434
Enter Participant Code: 7994216
Step 2: To join the web portion:
Click on link: https://studio7communications.adobeconnect.com/cibrn_dermatology/
Enter your name
Prior to the webinar, you are invited to visit the CIBRN community on Sosido to review the questions & responses and to reply with your personal clinical perspectives. The webinar will be recorded and archived for future viewing by the CIBRN community.
If you have any comments or questions, please contact me at your convenience.
If you have never attended an Adobe Connect meeting before:
Test your connection: https://studio7communications.adobeconnect.com/common/help/en/support/meeting_test.htm
Get a quick overview: http://www.adobe.com/products/adobeconnect.html
We invite you to listen to an in-depth discussion of CIBRN Question #3 & Question #4, as presented by Dr. Carter Thorne and Dr. Philip Baer, recorded at the CIBRN Rheumatology Webinar, December 1, 2016. Link to recorded webinar.
CIBRN Question #3: How confident can rheumatologists be in the results of the Nor-switch study to inform their biologic choices in everyday practice? Link to discussion on Sosido.
CIBRN Question #4: Given that patients in Nor-switch had been on an originator infliximab for a mean of 6+ years, is the rate of disease worsening over 1 year of 26-29% concerning regarding the face validity of the study? Link to discussion on Sosido.